Loading organizations...

§ Private Profile · Rehovot, HaMerkaz, Israel
MetaSight Diagnostics is a technology company.
MetaSight pioneers the development of accurate, affordable, and accessible disease diagnostics and monitoring through advanced blood testing, designed for high-volume population-scale screening.
MetaSight Diagnostics has raised $8.0M across 1 funding round.
MetaSight Diagnostics has raised $8.0M in total across 1 funding round.
MetaSight Diagnostics has raised $8.0M in total across 1 funding round.
MetaSight Diagnostics's investors include aMoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital.
MetaSight Diagnostics is a health technology company specializing in developing affordable, precise liquid biopsy diagnostics for early detection and monitoring of chronic and acute diseases. Their proprietary platform leverages cost-effective mass spectrometry technologies—metabolomics, lipidomics, and proteomics—combined with the world’s largest serum metabolomics dataset linked to longitudinal electronic health records. This enables high-throughput, sensitive, and scalable diagnostics designed for population-scale screening, targeting diseases such as colorectal cancer (CRC) and metabolic dysfunction-associated steatohepatitis (MASH)[1][2][3].
Founded in 2021 at the Technion – Israel Institute of Technology, MetaSight is led by Professor Tomer Shlomi, an expert in computer sciences and biology with a background in cancer metabolism and systems biology. The idea emerged from integrating multi-omics data with clinical records to accelerate biomarker discovery and reduce diagnostic development risks. Early traction includes raising $8 million in an oversubscribed Series A funding round to advance their pipeline and commercialize diagnostic products, with plans to launch tests in selected markets by 2025[1][2][4].
MetaSight rides the growing trend of precision medicine and non-invasive diagnostics, addressing the urgent need for early disease detection to improve outcomes and reduce healthcare costs. The timing is critical as healthcare systems increasingly adopt data-driven, scalable screening solutions. Their integration of multi-omics data with longitudinal health records positions them at the forefront of biomarker discovery and diagnostic innovation. This approach not only accelerates development timelines but also reduces risks, potentially reshaping the future of healthcare diagnostics and enabling more personalized, accessible care worldwide[1][2][3].
MetaSight is poised to expand its diagnostic offerings beyond CRC and MASH, leveraging its unique platform to target a broader range of diseases. The company’s growth will be shaped by advances in mass spectrometry, AI-driven data analysis, and increasing demand for early, affordable diagnostics. Strategic partnerships and market launches planned for 2025 will be pivotal. As healthcare moves toward population-scale precision diagnostics, MetaSight’s influence is likely to grow, potentially becoming a key player in transforming disease screening and monitoring globally[1][2][3].
MetaSight Diagnostics has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2024 | $8M Series A | — | Amoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital | Announced |